翻訳と辞書 |
Gene therapy for epilepsy : ウィキペディア英語版 | Gene therapy for epilepsy
Gene therapy is being studied for some forms of epilepsy. It aims to utilize viral and non-viral vectors in the delivery of DNA to target areas for the treatment of patients before their diseases progresses. Gene therapy has delivered promising results in animal trials and other pre-clinical settings, leading to being conducted in hopes of developing gene therapies for neurological disorders such as epilepsy. == Overview == Epilepsy is a chronic set of neurological disorders that are characterized by seizures, affecting over 50 million people, or 0.4% - 1% of the global population. There is a basic understanding of the pathophysiology and its existing treatments, including medication, surgery, and dieting. While these treatments are effective for many, there are approximately 20% - 30% who do not improve with antiepileptic drugs. As a result, many epileptics are left without any treatment options to consider, and thus there is a strong need for the development of innovative methods for treating epilepsy. Through the use of viral vector gene transfer, with the purpose of delivering DNA to targets for treatment, multiple neuropeptides have shown potential as targets for epilepsy treatment. Among those are adenovirus and adeno-associated virus vectors (AAV), which have the properties of high and efficient transduction, ease of production in high volumes, a wide range of hosts, and extended gene expression.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Gene therapy for epilepsy」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|